Bone marrow aspirate showing acute myeloid leukemia. Credit: VashiDonsk at English Wikipedia.

Daiichi Sankyo Company has dosed the first patient in the first in a Phase I trial evaluating the safety and activity of quizartinib in combination with milademetan (DS-3032) to treat patients with relapsed / refractory FLT3-ITD acute myeloid leukemia (AML).

The multi-centre, non-randomised, open-label trial will be conducted in two parts and will include newly-diagnosed FLT3-ITD AML patients who are unfit for intensive chemotherapy.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Part one of the study (dose escalation) will investigate the safety and tolerability of the drug combination to establish the dosing schedule, maximum tolerated dose and recommended dose for expansion.

The trial’s second part (dose expansion) will validate the safety and tolerability at the recommended dose for expansion of the study drug combination. This phase will also identify a recommended Phase II dose.

“We also are exploring the potential of the combination of quizartinib and milademetan in patients with newly-diagnosed FLT3-ITD AML who are unfit for intensive chemotherapy.”

Primary endpoint of the trial is safety, while its secondary endpoints include pharmacokinetics and preliminary efficacy.

Daiichi Sankyo aims to enrol around 110 patients in the US, Europe and Japan.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Daiichi Sankyo Oncology research and development vice-president Arnaud Lesegretain said: “We have initiated this combination study of quizartinib and milademetan in order to determine the safety and tolerability of the combination and if the addition of the MDM2 inhibitor milademetan may potentially further improve the outcomes of patients with relapsed / refractory FLT3-ITD AML beyond what has been previously reported with single agent quizartinib.

“In this study, we also are exploring the potential of the combination of quizartinib and milademetan in patients with newly-diagnosed FLT3-ITD AML who are unfit for intensive chemotherapy.”

Quizartinib is a FMS-like tyrosine kinase 3 (FLT3) inhibitor, while milademetan is a mouse double minute 2 homolog (MDM2) inhibitor.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact